

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/206307 A3

(51) International Patent Classification:

A61K 31/5375 (2006.01) A61P 25/22 (2006.01)
A61K 31/5377 (2006.01) A61P 25/24 (2006.01)
A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2024/021473

(22) International Filing Date:

26 March 2024 (26.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/454,930 27 March 2023 (27.03.2023) US

(71) Applicant: SUPERNUS PHARMACEUTICALS, INC.

[US/US]; 9715 Key West Ave., Rockville, Maryland 20850 (US).

(72) Inventors: PADIA, Janak Khimchand; c/o SUPERNUS PHARMACEUTICALS, INC., 9715 Key West Ave., Rockville, Maryland 20850 (US). YU, Chungping; c/o SU-

PERNUS PHARMACEUTICALS, INC., 9715 Key West Ave., Rockville, Maryland 20850 (US).

(74) Agent: MAEBIUS, Stephen B. et al.; FOLEY & LARDNER LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007-5109 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF

FIG. 1a

Percent Remaining of COMPOUND A in Human Plasma



(57) Abstract: A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R¹ is a substituted alkane group, a heterocyclic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester. Such compounds may be used in pharmaceutical compositions and for the treatment of central nervous system (CNS) disorders: (I)

[Continued on next page]

WO 2024/206307 A3

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

07 November 2024 (07.11.2024)